Shares of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) have received a consensus rating of “Buy” from the thirteen analysts that are currently covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $16.00.
Several equities research analysts have weighed in on SCMP shares. Zacks Investment Research upgraded Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a research note on Tuesday, October 17th. UBS dropped their price target on Sucampo Pharmaceuticals from $19.00 to $15.00 and set a “buy” rating for the company in a research note on Thursday, October 12th. began coverage on Sucampo Pharmaceuticals in a research note on Wednesday, November 15th. They issued a “buy” rating and a $14.00 price target for the company. Leerink Swann began coverage on Sucampo Pharmaceuticals in a research note on Monday, August 21st. They issued an “outperform” rating and a $15.00 price target for the company. Finally, B. Riley began coverage on Sucampo Pharmaceuticals in a research note on Tuesday, November 14th. They issued a “buy” rating and a $14.00 price target for the company.
Shares of Sucampo Pharmaceuticals (SCMP) opened at $12.70 on Friday. The company has a debt-to-equity ratio of 7.37, a quick ratio of 4.46 and a current ratio of 5.11. Sucampo Pharmaceuticals has a 52 week low of $9.30 and a 52 week high of $17.55. The company has a market capitalization of $533.98, a price-to-earnings ratio of 7.84, a P/E/G ratio of 3.41 and a beta of 1.38.
In other Sucampo Pharmaceuticals news, major shareholder Sachiko Kuno sold 1,000,000 shares of the stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $12.00, for a total transaction of $12,000,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Jason Patrick Meyenburg purchased 4,000 shares of the firm’s stock in a transaction on Wednesday, September 6th. The shares were acquired at an average price of $12.13 per share, with a total value of $48,520.00. Following the completion of the acquisition, the insider now owns 30,228 shares in the company, valued at approximately $366,665.64. The disclosure for this purchase can be found here. Corporate insiders own 4.13% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the business. AlphaMark Advisors LLC raised its stake in shares of Sucampo Pharmaceuticals by 25.4% during the second quarter. AlphaMark Advisors LLC now owns 98,400 shares of the biopharmaceutical company’s stock valued at $1,033,000 after acquiring an additional 19,900 shares during the last quarter. Swiss National Bank increased its stake in shares of Sucampo Pharmaceuticals by 22.3% in the 2nd quarter. Swiss National Bank now owns 43,859 shares of the biopharmaceutical company’s stock valued at $461,000 after buying an additional 8,000 shares during the period. Texas Permanent School Fund increased its stake in shares of Sucampo Pharmaceuticals by 2.2% in the 2nd quarter. Texas Permanent School Fund now owns 18,319 shares of the biopharmaceutical company’s stock valued at $192,000 after buying an additional 398 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Sucampo Pharmaceuticals by 1.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,570,172 shares of the biopharmaceutical company’s stock valued at $16,487,000 after buying an additional 15,528 shares during the period. Finally, Eqis Capital Management Inc. increased its stake in shares of Sucampo Pharmaceuticals by 28.5% in the 3rd quarter. Eqis Capital Management Inc. now owns 40,651 shares of the biopharmaceutical company’s stock valued at $480,000 after buying an additional 9,012 shares during the period. 65.12% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “Sucampo Pharmaceuticals, Inc. (SCMP) Receives Consensus Recommendation of “Buy” from Analysts” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/12/01/sucampo-pharmaceuticals-inc-scmp-receives-consensus-recommendation-of-buy-from-analysts.html.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.